Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2016 19:23 ET | Source: Idera Pharmaceuticals, Inc.

Datos prometedores de los informes farmacéuticos de Idera sobre la dosis escalonada de la fase 1 en curso en el ensayo clínico de IMO-2125 intratumoral en combinación con Ipilimumab en pacientes con melanoma metastásico refractario PD-1

- 3 pacientes con melanoma cutáneo refractario PD-1 que han respondido, incluyendo una respuesta completa (RC) – - A causa del incremento de la priorización del desarrollo clínico de IMO-2125, la...
September 26, 2016 19:23 ET | Source: Idera Pharmaceuticals, Inc.

アイデラ・ファーマシューティカルズ (Idera Pharmaceuticals)、実施中のPD-1治療抵抗性の転移性メラノーマ患者におけるイピリムマブ併用の腫瘍内IMO-2125の第1相試験の用量漸増試験で、有望なデータを報告

－ PD-1治療抵抗性の皮膚メラノーマの3人の患者に奏効し、そのうちの1人では完全奏効 (CR) を実現－－ IMO-2125の臨床開発の優先度が高くなったため、同社はB細胞リンパ腫治療のためのIMO-8400の開発を一時中止－セッツ州ケンブリッジおよびペンシルベニア州エクストン, Sept. 27, 2016 (GLOBE NEWSWIRE) --...
September 26, 2016 19:23 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Melaporkan Data Yang Memberansangkan daripada Peningkatan Dos Fasa 1 yang Berterusan dalam Ujian Klinikal IMO-2125 Intra-tumoral dalam Gabungan dengan Ipilimumab dalam Pesakit Melanoma Metastatik Refraktori PD-1

- 3 Pesakit dengan Melanoma Kutaneus Refraktori PD-1 adalah Penindak Termasuk Satu Respons Lengkap (CR) –- Dipacu oleh Pengutamaan Tambahan pada Pembangunan Klinikal IMO-2125, Syarikat Menggantung...
September 26, 2016 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic Melanoma

- 3 Patients with PD-1 Refractory Cutaneous Melanoma are Responders Including One Complete Response (CR) – - Driven by Increased Prioritization of IMO-2125 Clinical Development, Company Suspends...
August 24, 2016 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
August 12, 2016 09:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera to Present at the 2016 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
August 02, 2016 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 07, 2016 09:00 ET | Source: Aceragen, Inc.

Idera to Present at Two June Investor Healthcare Conferences

CAMBRIDGE, Mass. and EXTON, Pa., June 07, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
May 09, 2016 16:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update

9 of 10 Waldenstrom’s Macroglobulinemia Patients Treated at the Highest Dose have Demonstrated Reductions in IgM or M-Protein Levels in Ongoing TrialCompany is on Track to Deliver Data from 4 Clinical...
May 05, 2016 07:30 ET | Source: Aceragen, Inc.

Idera to Release 2016 First Quarter Results on May 9, 2016

CAMBRIDGE, Mass. and EXTON, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...